C Briani, G Zara, R Rondinone, L Iaccarino, S Ruggero, E Toffanin, M Ermani, A Ghirardello, S Zampieri, P Sarzi-Puttini, A Doria
BACKGROUND: Thalidomide is used in cutaneous lupus erythematosus (CLE) refractory to conventional therapies. Peripheral neuropathy (PN) is the most severe side effect, but the incidence of PN and its relation to thalidomide dose are still unclear. OBJECTIVE: To prospectively evaluate the efficacy as well as the occurrence of PN in CLE patients treated with thalidomide, and to assess whether PN, when occurs, correlates with thalidomide dose and/or length of treatment...
November 2005: Autoimmunity